Nextwave Drug Patent Portfolio

Nextwave owns 1 orange book drug protected by 7 US patents Given below is the list of Nextwave's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8287903 Orally effective methylphenidate extended release powder and aqueous suspension product 15 Feb, 2031
Active
US8465765 Orally effective methylphenidate extended release powder and aqueous suspension product 15 Feb, 2031
Active
US8563033 Orally effective methylphenidate extended release powder and aqueous suspension product 15 Feb, 2031
Active
US8778390 Orally effective methylphenidate extended release powder and aqueous suspension product 15 Feb, 2031
Active
US8956649 Orally effective methylphenidate extended release powder and aqueous suspension product 15 Feb, 2031
Active
US9040083 Orally effective methylphenidate extended release powder and aqueous suspension product 15 Feb, 2031
Active
US8062667 Modified release formulations containing drug-ion exchange resin complexes 29 Mar, 2029
Active


Given below is the list of recent legal activities going on the following drug patents of Nextwave.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 03 Apr, 2024 US8287903 (Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity 09 Nov, 2022 US9040083
Payment of Maintenance Fee, 8th Year, Large Entity 29 Dec, 2021 US8778390 (Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity 07 Apr, 2021 US8563033 (Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity 01 Oct, 2020 US8465765
Payment of Maintenance Fee, 8th Year, Large Entity 02 Apr, 2020 US8287903 (Litigated)
Payment of Maintenance Fee, 4th Year, Large Entity 15 Nov, 2018 US9040083
Payment of Maintenance Fee, 4th Year, Large Entity 04 Jan, 2018 US8778390 (Litigated)
Application ready for PDX access by participating foreign offices 31 Aug, 2015 US8778390 (Litigated)
Application ready for PDX access by participating foreign offices 31 Aug, 2015 US8563033 (Litigated)
Application ready for PDX access by participating foreign offices 31 Aug, 2015 US9040083
Recordation of Patent Grant Mailed 26 May, 2015 US9040083
Patent Issue Date Used in PTA Calculation 26 May, 2015 US9040083
Email Notification 07 May, 2015 US9040083
Issue Notification Mailed 06 May, 2015 US9040083


Nextwave's Family Patents

Nextwave drugs have patent protection in a total of 14 countries. It has a significant patent presence in the US with 58.3% of its patents being US patents. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree.

Family Patents



Nextwave Drug List

Given below is the complete list of Nextwave's drugs and the patents protecting them.


1. Quillivant Xr

Quillivant Xr is protected by 7 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8287903 Orally effective methylphenidate extended release powder and aqueous suspension product 15 Feb, 2031
(6 years from now)
Active
US8465765 Orally effective methylphenidate extended release powder and aqueous suspension product 15 Feb, 2031
(6 years from now)
Active
US8563033 Orally effective methylphenidate extended release powder and aqueous suspension product 15 Feb, 2031
(6 years from now)
Active
US8778390 Orally effective methylphenidate extended release powder and aqueous suspension product 15 Feb, 2031
(6 years from now)
Active
US8956649 Orally effective methylphenidate extended release powder and aqueous suspension product 15 Feb, 2031
(6 years from now)
Active
US9040083 Orally effective methylphenidate extended release powder and aqueous suspension product 15 Feb, 2031
(6 years from now)
Active
US8062667 Modified release formulations containing drug-ion exchange resin complexes 29 Mar, 2029
(4 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Quillivant Xr's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List